- Home
- NBH vs AVTX Comparison
NBH vs AVTX Comparison
Compare NBH & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$15.76
Company Overview
Basic Information| Metric | NBH | AVTX |
|---|---|---|
| Founded | 2002 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 303.6M | 248.3M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | NBH | AVTX |
|---|---|---|
| Price | $10.22 | $15.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $32.29 |
| AVG Volume (30 Days) | 85.9K | ★ 258.0K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 4.34% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.12 | N/A |
| Revenue | N/A | ★ $192,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $87.04 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.75 | $3.39 |
| 52 Week High | $11.01 | $20.72 |
Technical Indicators
Market Signals| Indicator | NBH | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 46.72 | 43.42 |
| Support Level | $10.07 | $14.52 |
| Resistance Level | $10.48 | $17.12 |
| Average True Range (ATR) | 0.07 | 1.23 |
| MACD | -0.00 | -0.11 |
| Stochastic Oscillator | 31.94 | 39.72 |
Price Performance
Historical Comparison NBH
AVTX
About NBH Neuberger Berman Municipal Fund Inc.
Neuberger Berman Municipal Fund Inc is a closed-end management investment company that invests mainly in municipal securities. The company aims to provide common stockholders a high level of current income exempt from Federal income tax.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).